Power of compounding intravitreal Bevacizumab - Experience from a tertiary eye care hospital

Background: Bevacizumab vials that are commercially available are fractionated into smaller quantities into the form of pre-filled syringes in a sterile and aseptic laboratory setting. Purpose: To share the long term experience of aliquoting of bevacizumab injections in a tertiary eye care center in...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of ophthalmology Vol. 70; no. 5; p. 1869
Main Authors Ramesh, Santosh, Sivaranjani, S, Hasmukhbhai, Nirav, Yadav, Divya
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer India Pvt. Ltd 01.05.2022
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Wolters Kluwer - Medknow
Wolters Kluwer Medknow Publications
Subjects
Angiogenesis Inhibitors
Bevacizumab
compounding
Hospitals
Humans
IJO Videos
intravitreal injection
Intravitreal Injections
Monoclonal antibodies
Patients
Syringes
Vascular Endothelial Growth Factor A
India
compounding
bevacizumab
intravitreal injection
Online AccessGet full text

Cover

More Information
Summary:Background: Bevacizumab vials that are commercially available are fractionated into smaller quantities into the form of pre-filled syringes in a sterile and aseptic laboratory setting. Purpose: To share the long term experience of aliquoting of bevacizumab injections in a tertiary eye care center in India. Synopsis: Compounding of bevacizumab was found to be a cost-effective and sustainable practice that has benefited more patients with an affordable cost, while maintaining high levels of quality. Highlights: Compounding of bevacizumab, when done with aseptic precautions can be a safe and cost-effective practice, the benefits of which can be passed on to needful patients. Video Link: https://youtu.be/C5XOpKHFkew
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0301-4738
1998-3689
DOI:10.4103/ijo.IJO_1016_22